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Background. The Thai-Cambodian border has been known as the origin of antimalarial drug resistance for
the past 30 years. There is a highly diverse market for antimalarials in this area, and improved knowledge of drug
pressure would be useful to target interventions aimed at reducing inappropriate drug use.
Methods. Baseline samples from 125 patients with falciparum malaria recruited for 2 in vivo studies (in Preah
Vihear and Pursat provinces) were analyzed for the presence of 14 antimalarials in a single run, by means of a
liquid chromatography–tandem mass spectrometry assay.
Results. Half of the patients had residual drug concentrations above the lower limit of calibration for at least
1 antimalarial at admission. Among the drugs detected were the currently used first-line drugs mefloquine (25%
and 35% of patients) and piperaquine (15% of patients); the first-line drug against vivax malaria, chloroquine
(25% and 41% of patients); and the former first-line drug, quinine (5% and 34% patients).
Conclusions. The findings demonstrate that there is high drug pressure and that many people still seek treatment
in the private and informal sector, where appropriate treatment is not guaranteed. Promotion of comprehensive
behavioral change, communication, community-based mobilization, and advocacy are vital to contain the emer-
gence and spread of parasite resistance against new antimalarials.
A few years ago, the World Health Organization
(WHO) recommended that conventional monothera-
pies—such as chloroquine, amodiaquine, and sulfa-
doxine-pyrimethamine—for the treatment of falcipa-
rum malaria should be replaced by artemisinin-based
combination therapies (ACTs), and today ACTs are
used as first-line treatment throughout the world [1–
4]. Initiatives to scale up control interventions and
eliminate malaria are critically dependent on the sus-
tained efficacy of ACTs. However, there is recent wor-
rying evidence of a reduced response to artemisinins
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arising on the Thai-Cambodian border [1, 5–13]. This
area has long been known as the origin of antimalarial
drug resistance. Parasites carrying resistance markers
against chloroquine, sulfadoxine-pyrimethamine, and
mefloquine were first found here before they appeared
elsewhere in the world [5, 6, 14]. In Cambodia, because
of poor transportation and public health infrastructure,
antimalarials were made available in the private sector
to increase access to the drug. While instrumental to
reaching out to more patients, this also led to uncon-
trolled use of these drugs. A recent study of malaria
treatment–seeking behavior in Cambodia showed that
180% of patients initially sought treatment from private
providers and pharmacies or consumed drugs on their
own [15]. Drugs from the private sector are often of
substandard quality, and the drug providers do not em-
phasize adherence. These key factors lead to treatment
failure and the development of resistance against chlo-
roquine, sulfadoxine-pyrimethamine, and mefloquine
in this area, and it is conceivable that the availability
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of artemisinin monotherapies, incorrect dosages, and poor drug
quality affected the response to artemisinin derivatives, too [7].
Several studies and programs are currently focusing on im-
proving the availability of quality-assured ACTs. In a study of
access to ACTs in remote areas of Cambodia, it was shown that
in the private sector up to 26% of patients received chloroquine,
22% received artemisinin monotherapy, and 12% received qui-
nine [16]. Treatment from private practitioners contained ar-
temisinin monotherapy in 34% of cases, chloroquine in 11%
of cases, and quinine in 13% of cases. Similar findings were
reported for public health facilities, where artesunate mono-
therapy and chloroquine each accounted for 11% of the treat-
ments given. Provision of free diagnosis and treatment through
trained village malaria workers were found to be effective means
of increasing ACT coverage in the studied settings. In 2008, a
baseline outlet and household survey was conducted in Cam-
bodia within the framework of ACTwatch [17]. The survey
assessed levels and trends in the availability, price, and volume
of antimalarials; providers’ perceptions and knowledge of an-
timalarials; consumer treatment-seeking behavior; and volumes
of specific antimalarials consumed. The findings are expected
to provide and promote evidence and recommendations for
policy makers on methods to increase availability and decrease
the consumer price of quality-assured ACT through the private
sector. WHO and several key partners from the ministries of
health and academia currently work on containing the spread
of artemisinin-resistant malarial parasites along the Thai-Cam-
bodian border. One of the key objectives of the collaboration
is to support the containment and elimination of artemisinin-
tolerant parasites through comprehensive behavioral change,
communication, community-based mobilization, and advocacy
[8, 9]. Knowledge of drug use in this specific area could help
in evaluating the effect of the interventions undertaken. The
present study aims at gathering information about circulating
antimalarials in 2 Cambodian provinces with different levels of
drug resistance and, thus, different recommended first-line
treatments. It was part of a multinational project aimed at
assessing the effect of the pharmacogenetic profile on the phar-
macokinetics of standard antimalarials (to be reported else-
where). Here, we report findings from the analysis of baseline
samples from patients with malaria recruited from 2 in vivo
studies for the presence of 14 currently-in-use antimalarials in
a single run, by means of a liquid chromatography–tandem
mass spectrometry (LC-MS/MS) assay [18].
METHODS
Study areas and populations. The study was performed in 2
rural areas with moderate transmission intensity during the
rainy season. Artesunate-mefloquine (Malarine) has been the
first-line treatment for Plasmodium falciparum infection since
2000 and was available at government health facilities as well
as in private structures through a social marketing program.
Chloroquine has been used as first-line treatment for Plas-
modium vivax infection. Artesunate, dihydroartemisinin, and
quinine can easily be found in the private sector without a
doctor’s prescription. At the time of the second study, dihy-
droartemisinin-piperaquine had been recently introduced as
first-line treatment in the study province because of low clinical
efficacy of the artesunate-mefloquine regimen and was available
only at government health facilities to ensure controlled use.
Clinical procedures. The trial was based on the standard
WHO protocol for in vivo testing [19]. The first study was
performed from October 2007 through February 2008 at the
Phnom De´k health center (Rovieng district, Preah Vihear prov-
ince, Cambodia), and the second study was performed from
July through October 2008 at the Pramoy health center (Veal
Veng district, Pursat province, Cambodia). Respectively, 234
and 287 suspected malaria cases were screened by microscopy.
Of these, 67 (29%) and 82 (29%) were infections with P. fal-
ciparum, and 74 (32%) and 50 (17%) were infections with P.
vivax. No mixed infections were detected. Adequate parasitemia
for enrollment in low to moderate transmission areas requires
at least 1 parasite for every 6 white blood cells, corresponding
to ∼1000 asexual parasites/mL. Patients with a positive slide
result for P. falciparum were then seen by the clinician, who
invited them to participate in the study if they were older than
6 months (in Phnom De´k) or 6 years (in Pramoy), not pregnant
or lactating, and did not present with danger signs of compli-
cated malaria or any other severe concomitant illness. Prior
reported treatment with antimalarial drugs was not considered
to be an exclusion criterion. After informed consent was pro-
vided by the patient, the baseline sample (day 0; 4.5 mL of
venous blood collected in an ethylenediaminetetraacetic acid
Vacutainer [Becton Dickinson]) was obtained for thick and thin
smears, hematocrit and drug blood concentration measure-
ments, and spotting on filter paper. In Phnom De´k, the national
standard first-line treatment introduced in 2000—artesunate
(Arsumax; Sanofi-Aventis) and mefloquine (Eloquine; Medo-
chemie) [7]—was given according to age. In Pramoy, patients
were treated with dihydroartemisinin-piperaquine (Duo-Co-
tecxin; Zhejiang Holley Nanhu Pharmaceutical Company) ac-
cording to age.
Laboratory procedures. Blood samples were immediately ali-
quoted into whole blood, plasma, and pellets and then stored in
liquid nitrogen. The samples were transferred to a 80C freezer
within 1 week. Plasma concentrations of 14 antimalarial drugs and
their metabolites—artemether, artesunate, dihydroartemisinin,
amodiaquine, N-desethyl-amodiaquine, lumefantrine,desbutyl-lu-
mefantrine, piperaquine, pyronaridine, mefloquine, chloroquine,
quinine, pyrimethamine, and sulfadoxine—were determined by
LC-MS/MS [18]. The lower limits of the calibration range (LLC)
in our method were selected as the lowest levels of the calibration
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Table 1. Residual Plasma Concentrations of Antimalarials






Mean Median Minimum Maximum
Mefloquine 16 260.3 152.5 12.6 987.0
Chloroquine 16 75.8 30.1 4.1 579.7
Quinine 3 72.1 4312.7 3.5 7550.8
NOTE. No artemether, artesunate, dihydroartemisinin, amodiaquine, N-de-
sethyl-amodiaquine, desbutyl-lumefantrine, lumefantrine, piperaquine, pyron-
aridine, sulfadoxine, or pyrimethamine was found.
Figure 1. Residual plasma concentrations of antimalarials found before
treatment in 64 patients with malaria from Preah Vihear. The number of
patients, median, 25th and 75th percentiles, lower and upper adjacent
values, and outlier values are shown for chloroquine, mefloquine, and
quinine.
curves, which confidently provide a bias and coefficient of variation
within20%, in accordance with Food and Drug Administration
recommendations [20]. All samples were analyzed twice. First,
quantitative measurement was performed using calibration and
quality control samples; then, for confirmation, qualitative assess-
ment was repeated using a new chromatographic column that had
not been exposed to any antimalarial drugs. To exclude contam-
ination and false-positive results, a large set of blank controls was
analyzed before the clinical samples on the new column, checking
for the absence of specific MS/MS signals for the antimalarials
investigated.
Sample size calculation. This sample size was based on the
assumptions made for the main multicentric study.
Data management and analysis. Summary statistics and
graphs of the residual plasma concentrations of antimalarials
found before treatment in the study population were produced
using Stata software (version 10.1, intercooled; StataCorp).
Estimation of dose intake time for mefloquine and
piperaquine. To estimate the probable timing of drug intake,
we compared the plasma concentrations of mefloquine in pa-
tients from Preah Vihear and the plasma concentrations of
piperaquine in patients from Pursat at baseline (C0) and on
day 14 (C14) after complete treatment with the respective drug
among the same patients. We included only patients for whom
we had both samples and who complied with the 3-day treat-
ment schedule. Assuming a mean terminal elimination half-
life ( ) of 15 (90% confidence interval [CI], 12.93–17.07)t1/2
days for mefloquine [21, 22] and of 27.8 (total range, 10.2–
216) days for piperaquine [23] and a similar dosage for prestudy
exposure and exposure during the study, a back-calculation was
done to estimate the intake time before baseline sampling, as
follows:
intake timep ln (C /C ) 7 t / ln (2) + 14 days .14 0 1/2
Similar calculations were not attempted for the other anti-
malarials (ie, chloroquine and quinine), because we did not
have the respective C0 and C14 values after standardized treat-
ment in the study patients.
Ethical approval. All applied protocols were approved by
the ethics committee of the 2 cantons of Basel (Ethikkommis-
sion beider Basel) and the responsible local authorities (Na-
tional Ethics Committee for Health Research, Cambodia).
Blood samples were obtained after receiving written informed
consent in Khmer from the participants or their responsible
guardians.
RESULTS
At the Phnom De´k health center, 64 patients were eligible and
willing to participate in the in vivo study. Of these 64 patients,
38 (59.4%) were male and 26 (40.6%) were female; their age
ranged from 2 to 57 years (median, 18 years). Parasite densities
ranged from 1200 to 160,000 asexual parasites/mL (median,
20,326 asexual parasites/mL). The presence of an antimalarial
drug was detected in the plasma of 33 patients (51.6%): 16
(25.0%) had a mefloquine concentration above the LLC of 2.5
ng/mL, 16 (25.0%) had a chloroquine concentration above the
LLC of 2.5 ng/mL, and 3 (4.7%) had a quinine concentration
above the LLC of 2.5 ng/mL; no other antimalarials tested were
detected. All patients reported either not having taken any an-
timalarials or not knowing. Parasite densities and age distri-
bution were comparable between patients with residual an-
timalarial concentrations on day 0 and those with no anti-
malarials—that is, 1200–142,857 asexual parasites/mL (median,
19,600 asexual parasites/mL) and 2–57 years (median, 19 years)
versus 3600–160,000 asexual parasites/mL (median, 21,052 asex-
ual parasites/mL) and 3–55 years (median, 16 years). Summary
statistics are shown in Table 1, and box plots of residual plasma
concentrations are shown in Figure 1. Of the 33 patients with
residual drug concentrations, 3 (9.1%) had them for 11 drug:
2 patients had residual chloroquine and mefloquine concen-
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Figure 2. Percentages of patients from Preah Vihear and Pursat with residual antimalarial concentrations. CQ, chloroquine; MQ, mefloquine; PPQ,
piperaquine; Q, quinine.
trations, and 1 had residual chloroquine and quinine concen-
trations (Figure 2). Of the 16 patients who had a residual mef-
loquine concentration, 12 also had a value for day 14; these 12
patients had a median plasma concentration of 52.8 ng/mL
(range, 12.6–987 ng/mL) on day 0. One patient had a plasma
concentration above the approximate in vivo minimum inhib-
itory concentration of mefloquine for resistant P. falciparum
(500 ng/mL) [24, 25]. On day 14, the median plasma concen-
tration was 757 ng/mL (range, 392–1135 ng/mL). This means
that a similar dosage level should have been administered at a
median of 68 days (interquartile range, 47–79 days; range 17–
102 days) before enrollment into the study, to account for the
levels observed on day 0. For 2 patients (17%), this estimate
was !28 days. Because there were only 3 late parasitological
failures on day 42, correlation between day 0 concentration and
treatment failure was not assessed. The variability in trans-t1/2
lates into 90% confidence intervals extending from 89% to
111% of estimates (median).
At the Pramoy health center, 61 patients were eligible and
willing to participate in the in vivo study. Of these 61 patients,
38 (62.3%) were male, and 23 (37.7%) were female; their age
ranged from 7 to 53 years (median, 18 years). Parasite densities
ranged from 1038 to 219,333 asexual parasites/mL (median,
16,975 asexual parasites/mL). The presence of an antimalarial
drug was detected in the plasma of 42 patients (68.9%): 25
(41.0%) had a chloroquine concentration above the LCC of
2.5 ng/mL, 21 (34.4%) had a mefloquine concentration above
the LCC of 2.5 ng/mL, 9 (14.7%) had a piperaquine concen-
tration above the LLC of 2 ng/mL, and 2 (3.3%) had a quinine
concentration above the LLC of 2.5 ng/mL; no other antima-
larials tested were detected. Only 6 patients stated that they had
taken antimalarials; the other patients reported not having
taken any antimalarials or not knowing. Age distribution was
comparable between patients with residual antimalarials on day
0 and those with no antimalarials—that is, 9–53 years (median,
18 years) versus 7–50 years (median, 18 years). As a result of
2 rather extreme values in the group with previous antimalarial
treatment, parasite densities differed slightly between the 2
groups—that is, 1038–219,333 asexual parasites/mL (median,
21,395 asexual parasites/mL) in the pretreated group versus
2451–114,666 asexual parasites/mL (median, 9522 asexual par-
asites/mL) in the group with no antimalarials at inclusion. Sum-
mary statistics are shown in Table 2, and box plots of residual
plasma concentrations are shown in Figure 3. Of the 42 patients
with residual drug concentrations, 12 (28.6%) had them for
11 drug: 1 (8.3%) patient had residual mefloquine and piper-
aquine concentrations, 1 (8.3%) had residual chloroquine and
piperaquine concentrations, 2 (16.7%) had residual mefloquine
and quinine concentrations, 5 (41.7%) had residual chloro-
quine and mefloquine concentrations, and 3 (25.0%) had re-
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Table 2. Residual Plasma Concentrations of Antimalarials





Mean Median Minimum Maximum
Chloroquine 25 80.8 16.8 2.6 919.5
Mefloquine 21 431.0 346.2 2.9 1202.4
Piperaquine 9 10.7 7.9 2.1 23.9
Quinine 2 8.6 8.6 4.2 12.9
NOTE. No artemether, artesunate, dihydroartemisinin, amodiaquine, N-de-
sethyl-amodiaquine, desbutyl-lumefantrine, lumefantrine, pyronaridine, sulfa-
doxine, or pyrimethamine was found.
sidual chloroquine, mefloquine, and piperaquine concentra-
tions (Figure 2). For piperaquine, among the 7 eligible patients
the median plasma concentration was 7.9 ng/mL (range, 6.1–
22.9 ng/mL) on day 0 and was 28.5 ng/mL (range, 18.8–56.3
ng/mL) on day 14. This means that a similar dosage level should
have been administered at a median of 67 days (interquartile
range, 53–81 days; range, 15–93 days) before enrollment into
the study, to account for the levels observed on day 0. For 1
patient (14%) this estimate was !28 days. Because there was
only 1 late parasitological failure on day 28, correlation between
day 0 concentration and treatment failure was not assessed.
The variability in (lowest and highest value measured fort1/2
[23]) translates into intervals extending from 50% to 632%t1/2
of estimates (median).
DISCUSSION
To our knowledge, this is the first study to investigate the pres-
ence of a broad range of antimalarials in the plasma of Southeast
Asian patients with malaria before treatment. The measurement
of 14 antimalarial drugs currently in use allowed a compre-
hensive assessment of all circulating drugs in the studied com-
munities in a region with high levels of antimalarial drug re-
sistance (Pursat province) and a region with moderate levels
of drug resistance (Preah Vihear province). Patients visiting a
health facility represent a selected group, because they might
be at a higher risk for repeated episodes of malaria (and hence
treatment) due to their exposure. Such a sample was used for
convenience in a pilot assessment.
Residual concentrations of former first-line treatments.
Although quinine is not recommended as first-line treatment
for uncomplicated falciparum malaria, it was found in 4.7%
and 3.3% of patients in Phnom De´k and Pramoy, respectively.
One patient had a quinine plasma concentration of 7.6 mg/L,
which corresponds to plasma concentrations during acute oral
treatment with ∼10 mg/kg quinine every 8 h [26, 27]. Fur-
thermore, we detected mefloquine in one-third of the study pa-
tients from Pursat, with 1 patient showing a plasma concentration
above the minimum inhibitory concentration. This shows that
people often buy their antimalarials from the private sector, given
that in 2008 the government changed the first-line treatment
along the border with Thailand from artesunate-mefloquine to
dihydroartemisinin-piperaquine and thus artesunate-mefloquine
was no longer available at government health facilities in western
Cambodia. Effective case management, including prompt diag-
nosis and treatment with an appropriate antimalarial, are not
guaranteed in the private sector. However, this is a key element
of the global strategy to eliminate malaria on a long-term basis
[28]. Comprehensive behavioral change of the population is ur-
gently needed to encourage them to seek appropriate manage-
ment (ie, laboratory diagnosis and ACT for malaria). Detection
of a drug with a long residence time does not allow determination
of whether a patient had taken it as monotherapy or as part of
an ACT or whether the complete dose had been taken. The
removal of monotherapies from the market in Cambodia must
be enforced, given that people with poor access to health facilities
tend to buy the cheapest antimalarial available in the private
sector regardless of its efficacy against the disease.
Residual concentrations of current first-line treatments.
We found that more than half of the patients carried residual
antimalarials at inclusion in our study. Although chloroquine
has been banned as first-line treatment for P. falciparum in-
fection, it could be detected in the plasma of 25.0% of the
patients in the Preah Vihear province and 41.0% of the patients
in the Pursat province. This might be explained by the fact that
chloroquine is the recommended first-line treatment for P. vi-
vax infection in Cambodia. We also detected residual concen-
trations of current first-line treatments in the study patients:
26.6% with mefloquine in Preah Vihear, where the first-line
treatment in 2007 was artesunate-mefloquine, and 14.7% with
piperaquine in Pursat, where the first-line treatment in 2008
was dihydroartemisinin-piperaquine. Assuming that the pa-
tients had taken mefloquine (in Preah Vihear) or piperaquine
(in Pursat) according to the 3-day treatment regimen, most
patients must have taken the regional first-line regimen 128
days before treatment in our study. It is also possible that
patients might have taken a subtherapeutic dose of these an-
timalarials more recently. However, as indicated by the large
variability in elimination half-life, these values represent only
rough estimates. The mean day 7 values observed in this study
for the 7 patients with a residual dihydroartemisinin-pipera-
quine concentration at inclusion (mean, 49.8 ng/mL [95% CI,
30.9–68.7 ng/mL]) were comparable to those from a study of
196 patients in Papua, Indonesia (mean, 46.6 ng/mL [95% CI,
43.3–49.8 ng/mL]) [29].
Artemisinins. In our study, it was not possible to detect
any of the artemisinins in the patients’ plasma because of the
short half-life of these compounds [30]. However, the possi-
bility that some of the patients might have taken one of the
artemisinins as monotherapy cannot be excluded. Considering
the high number of patients who did consume antimalarials
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Figure 3. Residual plasma concentrations of antimalarials found before treatment in 61 patients with malaria from Pursat. The number of patients,
median, 25th and 75th percentiles, lower and upper adjacent values, and outlier values are shown for chloroquine, mefloquine, quinine, and piperaquine.
that should not be used as therapy for uncomplicated falci-
parum malaria, it is possible that some might also have taken
an artemisinin as either combination therapy or monotherapy,
but this cannot be verified.
Potential bias in drug safety and efficacy assessment.
Previous antimalarial intake may interfere with the outcome of
the treatment under investigation. The present study shows that
only baseline drug concentration measurement in the blood can
be reliably used for the purpose. Our LC-MS/MS assay covers
14 antimalarials in a single run. We can confidently exclude a
lack of specificity and false-positive result, because we included
blank plasma samples as negative controls and systematically
repeated the measurement on a new chromatographic column.
Previous drug intake may affect the current treatment in several
ways. Higher drug exposure resulting from cumulative levels may
lead to better efficacy or more toxicity. In addition, the parasites
causing the disease at the time of enrollment may be a less
sensitive population selected by the previous treatment, and pa-
tients might be considered as already experiencing treatment
failure at inclusion.
High drug pressure. The likelihood of selecting for drug-
resistant parasites is highest with subtherapeutic levels of a
single drug. Thus, it is worrying that patients with low residual
concentrations of the long-lived antimalarials (mefloquine and
piperaquine) present with a new episode of malaria before they
have completely cleared the antimalarial. Price et al [29] re-
ported that the mean plasma piperaquine concentration was
16.8 ng/mL (95% CI, 15.1–18.6 ng/mL) on day 28. In our study,
the mean plasma piperaquine concentration on day 0 was 10.7
ng/mL. It is therefore likely that most patients had taken their
piperaquine treatment as symptomatic treatment of a fever ep-
isode or as treatment of a confirmed malaria episode 11 month
before inclusion. The persisting high drug pressure of meflo-
quine facilitates the spread of multidrug-resistant parasites from
western to northern and eastern Cambodia, where parasites are
still susceptible to mefloquine. The loss of artesunate-meflo-
quine as a treatment option for malaria in resource-poor areas
such as rural Cambodia would lead to a higher burden of
disease due to treatment failure. The efforts of the Ministry of
Health to restrict the use of dihydroartemisinin-piperaquine
only to areas of high drug resistance seems to be negated by
the nonadherence of the susceptible population to bed net–use
recommendations and a lack of appropriate treatment seeking
behavior for first-line antimalarial combination therapy in the
private and informal sector. On the other hand, the high num-
ber of patients taking antimalarial drugs on day 0 implies good
drug coverage and highlights the favorable habit of using ACTs
for episodes of fever even at the community level.
The present study shows that many persons still seek treat-
ment in the private and informal sector, which does not nec-
essarily follow national treatment policies. The emergence and
spread of parasite resistance against antimalarials along the
Thai-Cambodian border can be contained only via compre-
hensive behavioral change, communication, community-based
mobilization, and advocacy. Indeed, with the help of Global
Fund grants, the Ministry of Health has been encouraging easy
access to first-line treatment through free delivery at all health
centers as well as a large social marketing campaign in the
private sector, focusing on diagnostics and providing ACTs at
a low price. Recently, Cambodia was chosen to be part of the
Affordable Medicines Facility–malaria initiative, an innovative
financing mechanism designed to expand access to ACTs. Thus,
the availability of good drugs at a low price should be sustained
throughout the whole country. Currently, the Ministry of
Health is extending the use of the well-tolerated dihydroarte-
misinin-piperaquine treatment. Adherence to this ACT is ex-
pected to be higher than that for artesunate-mefloquine, the
less well-tolerated standard treatment in use since 2001. The
challenge will still be to restrict the use of first-line ACTs to
1094 • JID 2010:202 (1 October) • Hodel et al
confirmed malaria cases and hence ensure appropriate use of
antimalarials.
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